<?xml version="1.0" encoding="UTF-8"?>
<fig fig-type="Figure" xml:lang="en" id="jcsm12316-fig-0006" orientation="portrait" position="float">
 <label>Figure 6</label>
 <caption>
  <p>Impact of PLX‐PAD on the immune system. 
   <italic>(A, B)</italic> PLX‐PAD therapy does not amplify surgery‐induced immune suppression. 
   <italic>(A)</italic> Monocyte function (number of HLA‐DR molecules per monocyte) shows a decrease after surgery almost below the values of immune paralysis (8000 molecules/cell), which is not altered by immunomodulation by PLX‐PAD cells. 
   <italic>(B)</italic> Plasma IL‐6 levels correlate with the extent of surgical trauma and are unaffected by cell therapy. 
   <italic>(A)</italic> and 
   <italic>(B)</italic>: Total values over time. 
   <italic>(C, D)</italic> Prevention of surgical stress‐related early changes of immune cell subset composition by PLX‐PAD‐therapy. 
   <italic>(C)</italic> 1.5 × 10
   <sup>8</sup> PLX‐PAD cells prevented a post‐operative increase of CD16+ NK cells immediately after surgery (
   <italic>p</italic> &lt; 0.001) and 
   <italic>(D)</italic> immediate post‐operative decrease of CD4+ T‐cells (
   <italic>p</italic> &lt; 0.001) high‐dose group with 3.0 × 10
   <sup>8</sup> PLX‐PAD cells exhibited same pattern but with less pronounced effect (CD16+ NK cells: Day 1 
   <italic>P</italic> = 0.06 vs. placebo, 
   <italic>P</italic> = 0.074 vs. 150 M, CD4+ T‐cells: Day 1 
   <italic>P</italic> = 0.04 vs. placebo, 
   <italic>P</italic> = 0.08 vs. 150 M). Data given as change vs. baseline (mean ± SE). Repeated measures analysis of covariance, model adjusted means, modified intention to treat cohort. Preoperative baseline values 
   <italic>(C)</italic> as mean ± SE: Placebo: 15.1 ± 9.6%, 150 M: 11.0 ± 4.0%, 300 M: 16.7 ± 8.2%. Preoperative baseline values 
   <italic>(D)</italic> (mean ± SE): Placebo: 73.5 ± 7.7%, 150 M: 70.2 ± 12.6%, 300 M: 68.0 ± 5.5%. Significant values: Asterisk. 
   <italic>(E, F)</italic> The high‐dose group displays a late rise in inflammatory parameters indicating an unspecific inflammatory reaction. 
   <italic>(E)</italic> PLX‐PAD therapy prevented an early rise of plasma IL‐10 levels, but the high‐dose induced a late increase in plasma IL‐10. In the low‐dose group, plasma IL‐10 remained at placebo levels from day 2. 
   <italic>(F)</italic> IFN‐γ ELISA demonstrated increased inflammation 6 weeks after high‐dose therapy (300 M vs. placebo: 
   <italic>P</italic> = 0.002), which slightly decreased until week 52 (300 M vs. placebo: 
   <italic>P</italic> = 0.02). Low‐dose group exhibited placebo values. Preoperative baseline values 
   <italic>(E)</italic> as mean ± SE: Placebo: 5 ± 0 pg/mL, 150 M: 6.8 ± 4.8 pg/mL, 300 M: 5.2 ± 0.5 pg/mL. Preoperative baseline values 
   <italic>(D)</italic> (mean ± SE): Placebo: 2.6 ± 1.9, 150 M: 4.3 ± 3.7, 300 M: 1.8 ± 1.7. Significant values: Asterisk.
  </p>
 </caption>
 <graphic id="nlm-graphic-11" xlink:href="JCSM-9-880-g006" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
